Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY(®)) Antibody–Drug Conjugate in Sprague Dawley Rats

Polatuzumab vedotin (or POLIVY(®)), an antibody–drug conjugate (ADC) composed of a polatuzumab monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a cleavable dipeptide linker, has been approved by the United States Food and Drug Administration (FDA) for the treatment of diffuse lar...

Descripción completa

Detalles Bibliográficos
Autores principales: Yip, Victor, Lee, M. Violet, Saad, Ola M., Ma, Shuguang, Khojasteh, S. Cyrus, Shen, Ben-Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004598/
https://www.ncbi.nlm.nih.gov/pubmed/33806916
http://dx.doi.org/10.3390/jcm10061323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004598/
https://www.ncbi.nlm.nih.gov/pubmed/33806916
http://dx.doi.org/10.3390/jcm10061323

Ejemplares similares